8-KOther EventsExhibits & Filings

Medtronic plc 8-K Report, Corporate Update (Mar 22, 2017)

Filed March 22, 2017For Securities:MDT

Summary

Medtronic plc (MDT) filed an 8-K on March 22, 2017, to report on significant debt financing activities. The company, through its subsidiaries Medtronic Global Holdings S.C.A. and Medtronic, Inc., entered into underwriting agreements to issue a substantial amount of senior notes. Specifically, Medtronic Luxco agreed to issue $1.0 billion in 1.700% senior notes due 2019 and $850 million in 3.350% senior notes due 2027. Additionally, Medtronic, Inc. issued $150 million in 4.625% Senior Notes due 2045, which are a further issuance and form a single series with existing notes. These offerings are expected to generate approximately $2.0 billion in net proceeds, which Medtronic plans to use for general corporate purposes. The notes are fully guaranteed by Medtronic plc and its relevant subsidiaries, indicating a strong commitment from the parent company. Investors should note that this filing pertains to debt issuance and not equity, and the proceeds are for general corporate use, suggesting potential investments in operations, acquisitions, or debt refinancing.

Key Highlights

  • 1Medtronic plc, via subsidiaries, issued $1.85 billion in senior notes through Medtronic Luxco.
  • 2Medtronic Luxco issued $1 billion of 1.700% senior notes due 2019.
  • 3Medtronic Luxco issued $850 million of 3.350% senior notes due 2027.
  • 4Medtronic, Inc. issued an additional $150 million of its outstanding 4.625% Senior Notes due 2045.
  • 5Total net proceeds from these offerings are expected to be approximately $2.0 billion.
  • 6Proceeds are designated for general corporate purposes.
  • 7All new notes are fully and unconditionally guaranteed by Medtronic plc and related entities.

Frequently Asked Questions

This 8-K filing primarily serves to announce Medtronic plc's significant debt financing activities through its subsidiaries. It details the issuance of new senior notes totaling approximately $2.0 billion and outlines the terms and guarantees associated with these offerings.

The net proceeds from these note offerings are expected to be approximately $2.0 billion and will be used by Medtronic for general corporate purposes. This could include funding operations, strategic investments, potential acquisitions, or managing existing debt obligations.

Yes, all obligations related to the newly issued Luxco notes are fully and unconditionally guaranteed by Medtronic plc and Medtronic, Inc. The 2045 notes are also guaranteed by Medtronic Luxco and Medtronic plc, indicating strong support from the parent company for this debt issuance.

Medtronic Luxco issued $1 billion of 1.700% senior notes due 2019 and $850 million of 3.350% senior notes due 2027. Medtronic, Inc. issued an additional $150 million of its 4.625% Senior Notes due 2045.